Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Sutro Biopharma (STRO) has disclosed Operating Leases for 5 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 49.66% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, down 49.66% year-over-year, with the annual reading at $7.9 million for FY2025, 49.66% down from the prior year.
  • Operating Leases hit $7.9 million in Q4 2025 for Sutro Biopharma, down from $9.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $32.1 million in Q3 2021 to a low of $7.9 million in Q4 2025.
  • Historically, Operating Leases has averaged $22.6 million across 5 years, with a median of $24.0 million in 2023.
  • Biggest five-year swings in Operating Leases: fell 3.23% in 2022 and later tumbled 49.66% in 2025.
  • Year by year, Operating Leases stood at $31.2 million in 2021, then fell by 5.28% to $29.6 million in 2022, then fell by 21.71% to $23.2 million in 2023, then tumbled by 32.31% to $15.7 million in 2024, then crashed by 49.66% to $7.9 million in 2025.
  • Business Quant data shows Operating Leases for STRO at $7.9 million in Q4 2025, $9.7 million in Q3 2025, and $11.5 million in Q2 2025.